The USFDA issued six observations to Granules India’s Gagillapur facility in Hyderabad after an inspection between August 26 and September 6. The company is committed to addressing these issues promptly and will submit its response within the stipulated time frame. Following this news, Granules India’s stock fell by over 16% on the BSE.
Related Posts
This billionaire American CEO thinks you may work just 3.5 days a week in future
JPMorgan Chase CEO Jamie Dimon envisions a future with 3.5-day workweeks thanks to AI automating up to 70% of tasks. He believes AI will enhance […]
Per capita income to nearly double in 5 years: Finance minister Sitharaman
India is projected to nearly double its per capita income in the next five years, driven by government reforms, dynamic geopolitical changes, and strong growth […]
Saharanpur, Rewa, Ambikapur get wings with UDAN airports
Prime Minister Narendra Modi inaugurated new airports in Madhya Pradesh, Chhattisgarh, and Uttar Pradesh under the UDAN scheme. These airports aim to boost regional connectivity […]